tirzepatide cvot A comparison of the effects of and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial Tirzepatide Demonstrates Cardioprotective Effects in

Emerging preclinical and clinical evidence suggests these medications may modulate reward-seeking behaviour and reduce the reinforcing effects of alcohol, though this remains an area of active investigation rather than established clinical practice

10.1080/10799893.2020.1719517 51 MapangaR

For many people, this is a positive benefit, but when you introduce a prescription medication that performs a similar function, the situation becomes more complex

Published 2014 Mar 7

demonstrated that T2D patients that switched from glibenclamide to gliclazide, titrating the dosage to reach the same glycemic control as the previous treatment (glibenclamide), exhibited a reduction in serotonin-induce platelet aggregates formation compared to that on glibenclamide treatment (Konya et al., 2010) (Table 1)